Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Operating Leases: 2020-2024

Historic Operating Leases for Adma Biologics (ADMA) over the last 5 years, with Dec 2024 value amounting to $8.6 million.

  • Adma Biologics' Operating Leases rose 6.00% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 6.00%. This contributed to the annual value of $8.6 million for FY2024, which is 12.46% down from last year.
  • Per Adma Biologics' latest filing, its Operating Leases stood at $8.6 million for FY2024, which was down 12.46% from $9.8 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Operating Leases ranged from a high of $10.7 million in FY2022 and a low of $4.3 million during FY2020.
  • For the 3-year period, Adma Biologics' Operating Leases averaged around $9.7 million, with its median value being $9.8 million (2023).
  • In the last 5 years, Adma Biologics' Operating Leases soared by 72.18% in 2021 and then fell by 12.46% in 2024.
  • Over the past 5 years, Adma Biologics' Operating Leases (Yearly) stood at $4.3 million in 2020, then soared by 72.18% to $7.5 million in 2021, then spiked by 43.44% to $10.7 million in 2022, then dropped by 8.64% to $9.8 million in 2023, then dropped by 12.46% to $8.6 million in 2024.